Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
FibroGen, Inc.
FibroGen licenses oral HIF-PH inhibitors to Astellas for treating anemia in other countries
June 2nd, 2006
FibroGen, Inc. (FibroGen) announced it has completed an exclusive licensing agreement with Astellas Pharma Inc. (Astellas) that provides Astellas rights to certain FibroGen hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for development and marketing for the treatment of anemia in Europe, Commonwealth of Independent States (CIS), Middle East, and South Africa. These inhibitors include FG-2216 and FG-4592, currently in human clinical trials. FibroGen retains rights in the rest of the world except in Japan. The Japan rights were licensed previously to Astellas. "We are very pleased to broaden our relationship with Astellas, a highly...
Source: Medicine & Law Weekly (2006-06-02)
|
